Get the Stockscreener App
1.81
4.62%
0.08
Pre-market:
1.80
-0.01
-0.55%
Bioxcel Therapeutics Inc stock is traded at $1.81, with a volume of 213.59K.
It is up +4.62% in the last 24 hours and down -11.71% over the past month.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
See More
Previous Close:
$1.73
Open:
$1.78
24h Volume:
213.59K
Relative Volume:
0.71
Market Cap:
$10.96M
Revenue:
$1.38M
Net Income/Loss:
$-179.05M
P/E Ratio:
-0.2948
EPS:
-6.14
Net Cash Flow:
$-155.03M
1W Performance:
-5.24%
1M Performance:
-11.71%
6M Performance:
+432.35%
1Y Performance:
+54.70%
1-Day Range:
$1.75
$1.83
1-Week Range:
$1.695
$1.95
52-Week Range:
$0.16
$6.83
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Name
Bioxcel Therapeutics Inc
Sector
Industry
Phone
203-643-8060
Address
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.81 | 10.48M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-24 | Downgrade | UBS | Buy → Neutral |
| Aug-15-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-10-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-01-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-06-22 | Reiterated | BofA Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-30-20 | Initiated | Goldman | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Aug-17-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-04-20 | Initiated | Guggenheim | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
View All
Bioxcel Therapeutics Inc Stock (BTAI) Latest News
Mizuho slashes BioXcel Therapeutics stock price target to $2 from $16 - Investing.com
What is the risk reward ratio of investing in BioXcel Therapeutics Inc. stockTriple-digit wealth increases - jammulinksnews.com
What are BioXcel Therapeutics Inc. company’s key revenue driversCapitalize on market trends with confidence - jammulinksnews.com
What are the technical indicators suggesting about BioXcel Therapeutics Inc.Exceptional profit velocity - jammulinksnews.com
Is it the right time to buy BioXcel Therapeutics Inc. stockBuild a winning investment portfolio - jammulinksnews.com
Does BioXcel Therapeutics Inc. stock perform well during market downturnsDiscover breakthrough stocks before the crowd - jammulinksnews.com
How high can BioXcel Therapeutics Inc. stock price go in 2025Free Discussion Group - Metal.it
What analysts say about BioXcel Therapeutics Inc. stockFree Predictions - PrintWeekIndia
BioXcel Therapeutics Inc. Stock Analysis and ForecastRapid wealth accumulation - PrintWeekIndia
Is BioXcel Therapeutics Inc. a good long term investmentBreakthrough capital growth - PrintWeekIndia
Is BioXcel Therapeutics Inc. stock a good hedge against inflationBreakneck growth rates - jammulinksnews.com
What drives BioXcel Therapeutics Inc. stock priceFree Stock Market Real-Time Monitoring - Autocar Professional
BioXcel stock holds Buy rating at H.C. Wainwright ahead of FDA meeting - Investing.com Canada
BioXcel Therapeutics: Buy Rating Affirmed Amidst Pre-sNDA Submission and Upcoming SERENITY At-Home Trial Results - TipRanks
BioXcel Therapeutics Submits Pre-Supplemental New Drug - GlobeNewswire
Bioxcel Therapeutics' Strategic Move to Expand IGALMI for At-Home Use: Assessing the Market Opportunity and Regulatory Pathway for First-in-Class Agitation Treatment in Outpatient Mental Health - AInvest
BioXcel schedules FDA meeting for IGALMI outpatient use expansion - Investing.com
BioXcel schedules FDA meeting for IGALMI outpatient use expansion By Investing.com - Investing.com Nigeria
BTAI files pre-sNDA to expand IGALMI label for home use | BTAI SEC FilingForm 8-K - Stock Titan
Bioxcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package In Support Of Potential Label Expansion For Igalmi - TradingView
First-Ever At-Home Agitation Drug: FDA to Review IGALMI for 23M Patient Market Opportunity - Stock Titan
why bioxcel therapeutics inc. stock attracts strong analyst attentionStable Growth Stock Picks - Newser
What makes BioXcel Therapeutics Inc. stock price move sharplyAI Powered Stock Call - Newser
BioXcel Therapeutics Receives Steady Buy Rating from Lucid Capital Markets, Price Target Unchanged at $66.00 - AInvest
BTAI: BioXcel Therapeutics Receives Steady Buy Rating from Lucid Capital Markets | BTAI Stock News - GuruFocus
Bioxcel Therapeutics Inc Stock (BTAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):